Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high‑need indications, including pain.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Xenon Pharmaceuticals Inc. (XENE) reported revenue of $0 in Q1 2026 (quarter ended March 31, 2026), down 100% from the same quarter a year earlier. That came with net loss of $102M. For the full year FY2025, revenue was $7.5M and net income −$346M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.